Illumina (ILMN) Stock Sees Modest Fair Value Lift As Analysts Debate Growth Outlook
Missed Illumina's 76% Run? Here Is What Holders Saw
How Investors May Respond To Illumina (ILMN) Earnings Beat
Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
Illumina Bets on Clinical Demand for Growth as Research Funding Uncertainty Persists
Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript
Illumina Exec Says 2027 Is On Track For High-Single-Digit Revenue Growth And At Least A 25.5% Operating Margin As A Starting Point, But It Is Not Giving 2027 Forecast
Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
Illumina Launches Early Access Program To Support Ultrasensitive Research Into Molecular Residual Disease And Tumor Evolution
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
REGN vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Selected For Singapore Genome Sequencing Program Covering 450,000 People
The top 5 analyst questions from Illumina’s Q3 earnings call
Citigroup Maintains Sell on Illumina, Raises Price Target to $210
Don't Overlook Illumina (ILMN) International Revenue Trends While Assessing the Stock
Illumina, Inc. 2026 Q3 - Results - Earnings Call Presentation
Illumina (ILMN) Stock Falls After Q3 Results Lift Guidance
Why Illumina (ILMN) shares are getting obliterated today
Illumina (ILMN) Stock Stays Reasonable After Raised 2026 Guidance
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.